Semaglutide: how it works and the products that contain it
How this page is paid for: When you start care through one of our links, the provider may pay Weight Care Edit a fee. Your monthly price stays the same. On this page the partners sit at the top. How we make money
The short answer
Semaglutide copies GLP-1, a hormone your gut releases after eating. It stimulates insulin and reduces glucagon in a glucose-dependent manner, delays gastric emptying and reduces calorie intake, likely through appetite effects. Low blood sugar can still occur, particularly with insulin or insulin secretagogues. It is sold as Ozempic and Rybelsus for diabetes and as Wegovy for weight.
Definition
Semaglutide is a GLP-1 receptor agonist used as the active ingredient in Novo Nordisk’s approved formulations. It is the active ingredient in Ozempic and in the Rybelsus and Ozempic tablets (type 2 diabetes), and in Wegovy injection and Wegovy tablets (weight management and heart-risk reduction).
Key facts
| Fact | Detail |
|---|---|
| Drug class | GLP-1 receptor agonist, 94% similar in sequence to human GLP-1 |
| Maker | Novo Nordisk |
| First approval | Ozempic, December 5, 2017[5] |
| Forms | Weekly injection; daily tablet |
| Brands | Ozempic, Ozempic tablets, Rybelsus (being phased out), Wegovy injection, Wegovy tablets |
| Generic | ANDA 220314 has tentative approval, which is not permission to market[6] |
| Compounded | Not FDA-approved; shortage over February 21, 2025[10] |
| Brand self-pay | Wegovy pen $349 a month, pill $149 to $299 (NovoCare)[12] |
| Compounded, online | $75–$349 a month |
| Prescription | Required |
Ask what semaglutide is and you'll get a brand name back: Ozempic, Wegovy, Rybelsus. They're all the same molecule, made by Novo Nordisk, in different doses, devices and labels. This page is about the molecule itself: how it works, what it has done in trials, and how the products differ.
Semaglutide works by copying a gut hormone
Semaglutide copies GLP-1, a hormone your gut makes after meals. The label describes it as a GLP-1 analog with 94% sequence similarity to the human hormone that “selectively binds to and activates the GLP-1 receptor” [3]. Natural GLP-1 lasts minutes in the blood. Semaglutide binds to albumin, a blood protein, and resists the enzyme that breaks GLP-1 down, and its elimination half-life is approximately one week. The labeled schedule still depends on the formulation: weekly injection or daily tablet.
- Glucose-dependent insulin effects. It raises insulin and lowers glucagon “in a glucose-dependent manner,” so the effect is strongest when blood sugar is high [4].
- Slower stomach emptying. Food leaves the stomach more slowly, so sugar enters the blood more gradually after meals.
- Less appetite. GLP-1 receptors sit in brain areas that regulate appetite, and in animal studies semaglutide reached and activated those areas [3].
- Fewer calories. The net result, in the label's words: semaglutide “decreases calorie intake.”
These mechanisms help explain glucose and weight effects; they are not a complete causal account of every clinical benefit or adverse reaction. Ozempic and Wegovy have distinct indications, and sharing a molecule does not make their formulations or doses interchangeable.
One molecule, several approved formulations
Semaglutide is the ingredient. Ozempic and Wegovy are two products made from it, with different labels, doses and devices, and the same goes for the tablets. Is semaglutide the same as Ozempic? Same drug, yes. Same product, no.
| Product | Form | Approved for | First approved |
|---|---|---|---|
| Ozempic | Weekly pen or prefilled syringe | Adults with type 2 diabetes: blood sugar; cardiovascular risk with established cardiovascular disease; kidney outcomes with chronic kidney disease | December 5, 2017 |
| Rybelsus | Daily tablet | Type 2 diabetes: blood sugar, heart risk in high-risk adults | September 20, 2019; listed “To Be Discontinued” June 4, 2026 [7] |
| Ozempic tablets | Daily tablet (newer Rybelsus formulation) | Same as Rybelsus | Renamed January 30, 2026 [8] |
| Wegovy injection | Weekly pen, syringe or FlexTouch; 7.2 mg HD pen | Weight: adults with qualifying obesity/overweight and ages 12+ with obesity; cardiovascular risk in adults with established cardiovascular disease and obesity/overweight; adult noncirrhotic MASH/F2–F3 (accelerated) | June 4, 2021; 7.2 mg added March 19, 2026 |
| Wegovy tablets | Daily tablet | Weight and heart-risk reduction in adults | December 22, 2025 [9] |
| Compounded semaglutide | Pharmacy-made | Not FDA-approved | Never approved |
Approval dates from Drugs@FDA and FDA approval letters. Rybelsus and Ozempic tablets are “not substitutable on a mg-to-mg basis,” per their label.
Is semaglutide the same as Wegovy? Again, same drug, different product. Wegovy’s injection label has a 7.2 mg option for selected adults needing additional weight reduction; that dose is not the regimen for every indication or pediatric patient. Ozempic injection has a different dose range and indications. The tablets have their own guide, our page on oral semaglutide.
Which semaglutide product is right for you? That's a label question first. Type 2 diabetes points to Ozempic or the tablets. Weight management or heart-risk reduction without diabetes points to Wegovy. A preference for a pill over a shot narrows it further. Our Ozempic vs Wegovy comparison sets the two injections side by side.
Approved uses depend on formulation, diagnosis and population
The indication belongs to the exact product. Ozempic injection’s three indications concern adults with type 2 diabetes, with established cardiovascular disease or chronic kidney disease required for the respective risk-reduction uses. Wegovy’s weight and cardiovascular indications have their own age, BMI and disease criteria. Its noncirrhotic MASH indication applies to adults with F2–F3 fibrosis and to the injection only; it does not require obesity or overweight [4] [3].
| Approved use | Brand | Trial behind it |
|---|---|---|
| Blood sugar in adults with type 2 diabetes | Ozempic; Rybelsus and Ozempic tablets | SUSTAIN and PIONEER programs |
| Cardiovascular event risk in adults with type 2 diabetes: established CVD for injection, high risk for tablets | Ozempic; Rybelsus and Ozempic tablets | SUSTAIN-6 [19]; SOUL for the tablets [2] [1] |
| Slower kidney decline in type 2 diabetes with kidney disease | Ozempic | FLOW [17] |
| Weight reduction and maintenance with qualifying obesity or overweight | Wegovy injection (adults; ages 12+ with obesity); Wegovy tablets (adults) | STEP 1 [14]; OASIS 4 [20] |
| Cardiovascular event risk in adults with established CVD and obesity or overweight | Wegovy injection and tablets | SELECT [16] |
| Noncirrhotic MASH with moderate to advanced F2–F3 liver fibrosis in adults | Wegovy injection (accelerated approval) | ESSENCE [18] |
Can you take semaglutide without diabetes? Yes, as Wegovy, which is labeled for people with or without diabetes. Ozempic's label is type 2 diabetes only, so using it for weight alone is off-label.
Trials studied weight, cardiovascular and kidney outcomes, and liver histology
In STEP 1, adults without diabetes on semaglutide 2.4 mg a week lost 14.9% of their weight over 68 weeks, against 2.4% on placebo, and half lost 15% or more [14]. In SELECT, 17,604 adults aged 45 or older with established cardiovascular disease, BMI 27 or higher and no diabetes had first composite cardiovascular events in 6.5% versus 8.0%. The HR 0.80 (95% CI 0.72–0.90) represents a 20% relative reduction in event hazard, not 20 percentage points [16].
| Trial | Who was studied | Result | Funded by |
|---|---|---|---|
| STEP 1 [14] | 1,961 adults with obesity or overweight, no diabetes, 68 weeks | Weight −14.9% vs −2.4% | Novo Nordisk |
| STEP 1 extension [15] | 327 selected participants; exploratory year after medication and lifestyle intervention withdrawal | Regained 11.6 of 17.3 points lost | Novo Nordisk authors |
| SELECT [16] | 17,604 adults with heart disease and BMI 27+, no diabetes | First composite events 6.5% versus 8.0%; HR 0.80 (95% CI 0.72–0.90) | Novo Nordisk |
| FLOW [17] | 3,533 adults with type 2 diabetes and kidney disease | Kidney/CV-death composite: 331 versus 410 first events; HR 0.76 (95% CI 0.66–0.88) | Novo Nordisk |
| ESSENCE, part 1 [18] | 800 adults with MASH and F2 to F3 fibrosis, 72-week interim | Steatohepatitis resolution without fibrosis worsening: 62.9% versus 34.3%; fibrosis improvement without steatohepatitis worsening: 36.8% versus 22.4% | Novo Nordisk |
| SUSTAIN-6 [19] | 3,297 adults with type 2 diabetes at high heart risk | Heart events 6.6% vs 8.9%; retinopathy complications HR 1.76 (95% CI 1.11–2.78) | Novo Nordisk |
| OASIS 4 [20] | 307 adults with obesity or overweight, no diabetes, 64 weeks | Weight −13.6% vs −2.2% on the 25 mg tablet | Novo Nordisk |
Every trial here was run with Novo Nordisk, which makes semaglutide. ESSENCE randomized 1,197 participants; these liver-histology results concern the first 800 at the planned 72-week interim analysis, not proof of fewer clinical liver events. FLOW’s primary composite includes cardiovascular death; the trial stopped early after a prespecified interim analysis.
The newest dose has its own numbers. FDA added the 7.2 mg Wegovy HD dose after two 72-week trials that the label calls Studies 8 and 9. In adults with obesity and no diabetes, weight fell 18.8% on 7.2 mg, 15.5% on 2.4 mg and 3.9% on placebo [3]. Across clinical trials with and without type 2 diabetes, the label reports more dysesthesia with the higher dose, an odd skin sensation such as tingling or burning: 22% on 7.2 mg against 6% on 2.4 mg.
The stopping result is the one most people don't hear. A year after STEP 1 participants came off semaglutide and the trial's lifestyle program, they had regained about two-thirds of the weight they'd lost, and blood pressure and other risk factors drifted back toward where they started [15]. This selected exploratory subgroup is not an individual forecast. Medication and lifestyle support ended together, so the extension does not isolate stopping the drug from stopping support.
Semaglutide causes weight loss mainly by cutting appetite
Semaglutide leads to weight loss because people eat less. The Wegovy label says it “decreases calorie intake,” that “the effects are likely mediated by affecting appetite,” and that it “lowers body weight with greater fat mass loss than lean mass loss” [3]. It also delays gastric emptying; this does not establish that a single mechanism explains every participant’s weight change or digestive symptom.
The label reports greater fat-mass than lean-mass loss, which does not mean lean tissue is completely spared. A trial’s mean weight change cannot assign how much of an individual’s result came from appetite, food intake, activity or other factors. Ask the clinician how nutrition, strength and clinical follow-up fit the treatment plan rather than treating the drug as a guarantee of selective fat loss.
Mechanistic explanations need limits. Delayed gastric emptying is a labeled effect, but it is not proof of the cause of every episode of nausea or every symptom after stopping. Persistent or severe symptoms require clinical assessment. The withdrawal evidence above concerns observed weight and risk-factor changes under specified study conditions.
Digestive effects and serious warnings differ by formulation and population
Every semaglutide product carries a boxed warning about thyroid C-cell tumors seen in rodents, and personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. Human relevance of the rodent findings is unknown; serious allergy to semaglutide or the product’s ingredients is another contraindication. The common side effects are gastrointestinal. In the label’s adult weight-management injection trials, 73% reported gastrointestinal events versus 47% on placebo; these were reported most frequently during escalation [3].
| Side effect | Placebo | Semaglutide 2.4 mg |
|---|---|---|
| Nausea | 16% | 44% |
| Diarrhea | 16% | 30% |
| Vomiting | 6% | 24% |
| Constipation | 11% | 24% |
| Abdominal pain | 10% | 20% |
| Headache | 10% | 14% |
| Fatigue | 5% | 11% |
These are pooled adult Wegovy 2.4 mg weight-management trial rates, not rates for every semaglutide formulation or a direct comparison with Ozempic. See the Ozempic page for its separate trial populations and table.
The labels also warn about pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration, allergic reactions, a faster heart rate and aspiration during anesthesia. In type 2 diabetes, SUSTAIN-6 found more diabetic eye complications on semaglutide (hazard ratio 1.76) [19]. In STEP 1, stomach side effects led 4.5% of people to stop, against 0.8% on placebo [14]. Brand-specific detail is in Wegovy side effects and Ozempic safety and side effects.
The generic name, tentative approval and compounding are different concepts
Semaglutide is itself the generic name; Ozempic and Wegovy are brand names. The cited FDA record for Apotex ANDA 220314 lists semaglutide injection with tentative approval dated April 7, 2026 [6]. The record lists tentative approval rather than approval to market. Do not treat that status as a product currently authorized for sale.
A tentative application record is not a complete inventory of future approvals. Ask what exact FDA-approved product an offer refers to. A pharmacy-compounded preparation does not become an FDA-approved generic because it contains the same named ingredient.
Compounded semaglutide is a distinct pharmacy preparation
Compounded semaglutide is not FDA-approved, and FDA does not review it for safety, effectiveness or quality before marketing [11]. The shortage affected certain restrictions on essentially-copy compounding, while other statutory requirements still applied. FDA declared the shortage over on February 21, 2025, and the grace periods for compounders ended that spring [10]. The current framework distinguishes patient-specific section 503A compounding from section 503B bulk-ingredient requirements. A seller’s availability claim does not establish compliance.
FDA reports 990 adverse-event reports associated with compounded semaglutide through May 31, 2026; these do not establish causality, incidence or comparative risk, and says salt forms such as semaglutide sodium have no known lawful basis for compounding [11]. Our guides cover compounded semaglutide, whether it will be banned and how it compares with Ozempic.
Tirzepatide produced more weight loss head to head; liraglutide produced less
Head to head, tirzepatide beat semaglutide on weight: −20.2% vs −13.7% at 72 weeks in SURMOUNT-5, an open-label trial of 751 adults with obesity without type 2 diabetes, funded by Eli Lilly. It compared maximum tolerated tirzepatide 10/15 mg with semaglutide 1.7/2.4 mg, not every current formulation or dose [21]. Against the older daily drug liraglutide, semaglutide won: −15.8% vs −6.4% at 68 weeks in STEP 8, a trial with Novo Nordisk authors, whose company makes both drugs [22].
See semaglutide vs tirzepatide for the full comparison, and our tirzepatide and liraglutide pages for each drug on its own.
Brand offers use different supply units and eligibility conditions
Brand semaglutide’s self-pay price depends on the product and offer eligibility. Wegovy’s quoted month is four pens or 30 tablets; Ozempic’s offer unit is one pen, whose time covered depends on the prescribed regimen. The lowest tablet strength is not a maintenance-dose budget. Clinical fees may be separate, offers can change or end, and cash payments outside insurance do not automatically count toward deductibles or out-of-pocket limits. Through NovoCare right now, the Wegovy pen is $349 a month, Wegovy HD is $399, the Wegovy pill is $149 to $299 by dose, and Ozempic is $349 to $499 [12] [13]. New patients pay $199 for their first two pen fills at the lowest doses, through December 31, 2026.
| Product | Doses | Self-pay a month | Note |
|---|---|---|---|
| Wegovy pen | 0.25 to 2.4 mg | $349 | $199 for first 2 fills (0.25, 0.5 mg) for new patients through December 31, 2026 |
| Wegovy HD pen | 7.2 mg | $399 | One month = 4 pens |
| Wegovy pill | 1.5 mg / 4 mg / 9 or 25 mg | $149 / $199 / $299 | One month = 30 tablets |
| Ozempic pen | 0.25 to 1 mg / 2 mg | $349 / $499 | Eligible new-patient intro; one-pen offer unit, not guaranteed calendar coverage |
Source: NovoCare savings pages. NovoCare says pricing will be updated after December 31, 2026.
A pharmacy-made offer needs a separate written quote: exact preparation, clinical fees, supply duration, renewal interval and pharmacy identity. Compare the SnagRx review and Found review for service and billing questions, and use the cost calculator to separate cash payment dates from an annualized monthly equivalent. A named pharmacy is a starting point for verification, not proof of assignment, product approval or independent quality assessment.
For the full picture, read what compounded semaglutide costs and what Wegovy costs, or see every program scored on the compounded semaglutide board and, for pills, the GLP-1 pill programs board.
Every form of semaglutide needs a prescription
Every semaglutide product needs a prescription, brand or compounded. Your own clinician can write it and send it to a local pharmacy or NovoCare Pharmacy. Telehealth programs also prescribe both brand and compounded versions after an online intake. If you're thinking about very small doses, our GLP-1 microdosing guide explains what hasn't been tested.
Research on Semaglutide
How to check the pharmacy behind an online GLP-1 program
Look past the checkout page: identify the dispensing pharmacy, verify its license and ask what product it will supply before paying for an online plan.
Your first weight-care appointment: what to bring and ask
Prepare your medicine list, treatment history, cost questions and follow-up preferences for a first weight-care visit. The clinician decides the care plan.
GLP-1 insurance coverage: the questions that decide your cost
Confirm the exact drug, indication and plan rules before joining a clinic. A membership price alone cannot tell you what your prescription will cost.
Before a GLP-1 prior authorization: organize the paperwork
A prior authorization is a plan decision, not a prescription guarantee. Here is how to organize the request and understand the answer without guessing.
Before joining a GLP-1 program: read the renewal and exit terms
A low monthly headline may require prepayment or leave medicine separate. Compare renewal charges, refund rules and care transfer before you join a program.
Compounded semaglutide prices: what you'll pay each month
What each online program keeps charging after month one, set next to the Wegovy pen and pill prices Novo Nordisk now sells direct.
Compounded semaglutide in the fridge: how long it keeps
Why a vial of compounded semaglutide gets 28 days once opened while an Ozempic pen gets 56, and which date to trust when they disagree.
Compounded semaglutide: maximum-dose claims and brand limits
A labeled maximum is part of a product’s FDA-approved prescribing information, and compounded semaglutide doesn’t have one. The approved semaglutide injections do. Here are their limits, what FDA has seen when compounded doses go past them, and what to ask about yours.
Does compounded semaglutide work as well as Wegovy?
The molecule has strong trial evidence behind it. Matching an ingredient name and labeled strength does not establish equivalent quality, safety or effectiveness for a compounded vial.
Medicare and Medicaid coverage for Ozempic in 2026
Which Medicare rule applies to you, what Part D costs in 2026 and 2027, why the $50 GLP-1 Bridge leaves Ozempic out, and how Medicaid differs by state.
Wegovy and tiredness: how common it is and what the label links it to
Fatigue is on Wegovy's label, at about 1 in 9 people. Here are the numbers, the causes the label names, and the kinds of tiredness that shouldn't wait.
Wegovy storage: fridge, room temperature and travel limits by device
The answer depends on which Wegovy you have. Here is the US label's rule for each device, what to do if it froze or got hot, and how to travel with it.
GLP-1 telehealth explained: routes, checks and FDA's red flags
The three ways to get a GLP-1 online, what a real medical evaluation asks, who fills the prescription, and the warning signs FDA tells you to look for.
Getting semaglutide online in 2026: compounded, brand or insurance
Prescription routes, the self-pay prices Novo Nordisk posts for the Wegovy pill and pen, and how to check a compounded program before you sign up.
How safe is compounded semaglutide? The risks FDA has documented
The known risks of semaglutide, the extra ones FDA has documented for compounded versions, and the checks you can run before your first dose.
Microdosing GLP-1 drugs: the claims, the evidence and the risks
Low-dose GLP-1 programs are sold for longevity, wellness and maintenance. Here is what the labels, the trials and the first real-world data actually show.
Bruising, itching and rash on Ozempic: what the label reports
A mark where you inject and a rash across your body are different things. Here's what Ozempic's label reports for each, and how to tell when a skin reaction is an emergency.
"Ozempic face": facial changes after GLP-1 weight loss, explained
Where the nickname comes from, what imaging studies have measured, who notices it most, and why "Ozempic teeth" has even less behind it.
How safe is Ozempic? What the label and two outcomes trials show
Ozempic's side effects with their placebo rates, the ten warnings on its label, what its heart and kidney trials found, and the people the label rules out.
Ozempic and your stomach: diarrhea, nausea, constipation and burping
Ozempic's own label numbers for every stomach side effect, what the label says about why they happen and when, and the few digestive symptoms that are emergencies.
Peeing, thirst, dry mouth and taste changes on Ozempic
Each sensation checked against Ozempic's prescribing information, with the limits of label-based answers and signs that need clinical assessment.
Wegovy side effects: what the label lists and how long they last
Every side effect on the current US label, with the placebo rate beside it, the timeline the trials describe, and the short list of symptoms that mean call today.
Wegovy and thyroid cancer: the boxed warning and the human evidence
Where the warning comes from, what two large studies of GLP-1 users found, why they disagree, and who shouldn't take Wegovy at all.
Is compounded semaglutide going away? What FDA has decided so far
Compounded semaglutide hasn't been banned in the U.S. But the rules that made it easy to get ended in 2025, FDA has ruled out salt forms, and a 2026 proposal could close one more door. Here's where things stand and what to do if your supply changes.
Semaglutide compared
Is compounded semaglutide the same as Ozempic? Not as a product
The name on the vial is the same molecule. Almost everything else differs: who checks it, what else is in it, how it's dosed and what evidence stands behind it. Here is each difference, with current prices for both.
Semaglutide vs tirzepatide: what the head-to-head trials found
One drug acts on one gut-hormone receptor, the other on two. Here's what that difference did in the trials that tested them directly.
Wegovy pill or Wegovy shot: cost, results and the trade-offs
Same molecule, same company, two very different routines. The pill is cheaper on NovoCare's cash prices and did nearly as well in its trial. The weekly pen covers more people and goes to a higher dose.
Wegovy or Mounjaro: start with which label fits you
Two different molecules from two different companies, approved for different people. Find your situation in the table and you'll know which label applies, and which drug is the fair comparison.
Compare providers
Compounded semaglutide providers, scored
26 programs on this list
Semaglutide programs that also treat menopause, scored
4 programs on this list
Semaglutide programs that also treat low testosterone, scored
11 programs on this list
Compounded semaglutide under $200 a month, scored
15 programs on this list
Compounded semaglutide programs in all 50 states, scored
9 programs on this list
Providers that offer Semaglutide
- Read the review →Visit site →
CoreAge RxPartner
You want compounded tirzepatide or semaglutide at one price for every dose, and you're comfortable paying before the doctor reviews your intake.
- Read the review →Visit site →
DirectMedsPartner
You want an online clinician evaluation and bundled supplies, and you will resolve the written billing and pharmacy details before choosing a plan.
- Read the review →Visit site →
Gala GLP-1Partner
You want compounded tirzepatide or semaglutide at one price for every dose, with an app and chat for the day-to-day, and you live anywhere in the US.
- Read the review →
AHBARx
You value a provider-described renewal reassessment and are willing to resolve the membership charge, exact prescriber, dispensing location and full commitment in writing before enrolling.
- Read the review →
altRx
You value a published flat-dose-price promise and disclosed clinical and pharmacy networks, and will clarify the renewal, dispensing and refund conditions before accepting a paid bundle.
- Read the review →
Arc-1
You want to investigate rapamycin alongside weight-care offers and will obtain product, renewal and refund details before accepting the subscription.
- Read the review →
ARSYNL Rx
You want a published monthly compounded-injection offer with named possible pharmacy partners, and will clarify the assigned care team, formulation and renewal terms.
- Read the review →
Bayan Health
You're settled on a compounded GLP-1 for the long haul and want one flat price at every dose, with the consult and shipping folded in.
- Read the review →
Belle
You want a published month-to-month GLP-1 price, provider-described dose-independent charges and named pharmacy options, and you will confirm the clinical and renewal arrangements before paying.
- Read the review →
Bionomy Health
You prefer pay-per-fill approval and no automatic membership renewal, and will verify the practitioner, dispensing location and exact order conditions.
- Read the review →
Brightmeds
You want published monthly GLP-1 charges with clinical review and can accept the advance cancellation deadline and pharmacy-disclosure limits.
- Read the review →
Chia
You want to compare monthly and committed GLP-1 offers and will obtain written clarification of the guarantee, payment, clinical contact and dispensing conditions.
- Read the review →
Collective
You plan to stay on a compounded GLP-1 for a year or more and want one price at every dose, with doctor messaging and regular check-ins included.
- Read the review →
Eden
You value the stated flat-dose service model and will obtain a clear written quote, applicable membership agreement and pharmacy identity before paying.
- Read the review →
EdgeRx
You're a man who wants a compounded GLP-1 with physician review folded into one monthly price, from a company that names its pharmacy and lets you stop any month.
- Read the review →
ElitePhysiqMD
You want a live video visit with a physician before you start, and you plan to stay long enough for the membership's free shipping and visit fees to pay off.
- Read the review →
ElleS
You want an online clinician evaluation and ongoing support, and you are comfortable requesting a complete written quote before deciding.
- Read the review →
Embody
You want a program that identifies its clinician network and pharmacy partners, and will confirm the complete financial agreement before paying.
- Read the review →
Enhance MD
You want labs and a live video visit built into a flat-priced compounded GLP-1 plan, and you like seeing the pharmacies and medical groups named.
- Read the review →
Found
You value a published 28-day price schedule and clinical-care insurance options, and can confirm the pharmacy, total cost and cancellation terms before committing.
- Read the review →
Goldspan Health
You want compounded tirzepatide or semaglutide with a monthly dose check-in, and you're comfortable paying for a lab panel within three months.
- Read the review →
HealthRX
You want a disclosed introductory and monthly GLP-1 renewal price, and can confirm supply coverage, injection supplies and the actual clinical and pharmacy assignment before paying.
- Read the review →
Henry Meds
You want compounded semaglutide injections with visits and supplies in one monthly bill, the option of a video visit, and no long-term contract.
- Read the review →
iThriveMD
You value access to a named care team and possible clinic visits, and can obtain a complete product-specific quote, prescriber identity and pharmacy details before enrolling.
- Read the review →
Live Vital
You want to talk to a named medical team before starting, see the full protocol total up front, and don't mind paying per 10-week protocol.
- Read the review →
Luvo Health
You want a disclosed twenty-eight-day plan structure and named partner disclosures, and can confirm the final quote, intake charge, pharmacy assignment and cancellation cutoff.
- Read the review →
Maximus
You want a brand GLP-1 pill such as Foundayo or Wegovy tablets at a printed cash price, from a provider that names its pharmacies.
- Read the review →
Neuvé MD
You want compounded semaglutide or tirzepatide with every price posted, a choice of injection or tablet, and dose changes folded into one monthly plan.
- Read the review →
Nex Gen Health Rx
You want advertised dose-independent GLP-1 pricing or a metformin discussion and will confirm the billing interval, actual pharmacy and clinical follow-up before purchase.
- Read the review →
Nu Image Medical
You want a licensed online evaluation and named pharmacy information, and you will obtain a product-specific written quote before committing to a multi-month supply.
- Read the review →
Oak
You are comparing longer plans, prefer messaging and want weight and related care in one account, after confirming the exact quote and consultation model.
- Read the review →
PlexusDx
You want published monthly and prepaid GLP-1 prices and a named clinical-group disclosure, and can confirm the charge event, pharmacy assignment and prepaid refund conditions.
- Read the review →
Prime Doctor RX
You value named clinical and pharmacy organizations and clear four-week billing, and will confirm the dose-specific total, monitoring and refund allocation before committing.
- Read the review →
RxSpan MD
You want an online clinician evaluation and ongoing support, and you are comfortable requesting a complete written quote before deciding.
- Read the review →
Shed
You want compounded tirzepatide or semaglutide with prices you can see up front, free follow-ups, and the choice of an injection, drops or a lozenge.
- Read the review →
SnagRx
You want compounded semaglutide or tirzepatide at one flat price for every dose, with the pharmacies named, and you're happy to pay month to month or commit to a longer plan up front.
- Read the review →
Strut Health
You value a public product menu and clinician messaging, and will confirm the refill calendar, dispensing pharmacy and formulation-specific evidence first.
- Read the review →
TeleZen MD
You want to compare a published monthly or quarterly program and can obtain a complete fee quote, refund terms and clinical and pharmacy assignments before paying.
- Read the review →
Try Ageless
You want to discuss a needle-free compounded format with an independent clinician and will obtain the complete product-specific quote, monitoring plan and pharmacy assignment before paying.
- Read the review →
Vita Bella
You want several longevity prescriptions, such as rapamycin, metformin, a GLP-1 or testosterone, under one provider who sees you every quarter, and you're fine paying a membership for that.
- Read the review →
Wellorithm
You want flat-dose published GLP-1 plans and will confirm the conflicting billing interval, renewal amount and dispensing pharmacy before paying.
- Read the review →
WePeptideRx
You want to see exactly what each dose of compounded tirzepatide or semaglutide will cost before you start, with the visit and shipping included.
- Read the review →
Willow
You want compounded semaglutide or tirzepatide at one simple monthly price, as a shot or a tablet, with physician review and ongoing portal messaging.
- Read the review →
YourHealthRx
You want published monthly pricing or a clearly identified prepaid option and will confirm the clinical partner, exact pharmacy, follow-up and refund allocation before enrolling.
- Read the review →
Youth & Soul
You want a compounded GLP-1 at a flat monthly price with no membership, or you'd rather try a lozenge or a spray than a weekly injection.
Frequently asked
- Is semaglutide the same as Ozempic?
- Ozempic contains semaglutide, so the drug is the same. Ozempic is one product made from it, approved for type 2 diabetes, in its own doses and pens.
- Is semaglutide the same as Wegovy?
- Wegovy also contains semaglutide. It's the product approved for weight management and heart-risk reduction, with higher doses than Ozempic and a daily pill version.
- What is semaglutide used for?
- Uses depend on the exact product and population. Injection/tablet diabetes indications differ from Wegovy weight and cardiovascular indications. Kidney risk reduction requires type 2 diabetes with chronic kidney disease; cardiovascular indications have disease or risk qualifiers. MASH treatment is injection-only in adults with noncirrhotic F2–F3 disease, and pediatric weight treatment is injection-only.
- Is there a generic for semaglutide?
- The cited FDA record for ANDA 220314 is tentative approval, which does not permit marketing. The chemical’s generic name is not proof that a product is an approved generic. Compounded semaglutide is not an FDA-approved generic.
- How does semaglutide work for weight loss?
- It reduces appetite and calorie intake by acting on GLP-1 receptors, including in the brain, and slows stomach emptying. People eat less, and the labels say more fat than lean mass is lost.
- Does semaglutide work as a pill?
- Yes. Wegovy tablets are a daily semaglutide pill approved for weight. In OASIS 4, the 25 mg tablet cut weight 13.6% vs 2.2% on placebo over 64 weeks.
Sources
- [1] Rybelsus and Ozempic tablets, prescribing information (2026). DailyMed label
- [2] McGuire DK. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (2025). PMID 40162642
- [3] Wegovy (semaglutide) injection and tablets, prescribing information (2026). DailyMed label
- [4] Ozempic (semaglutide) injection, prescribing information (2026). DailyMed label
- [5] Drugs@FDA: Ozempic, NDA 209637 (2026). FDA
- [6] Drugs@FDA: semaglutide injection, ANDA 220314 (tentative approval) (2026). FDA
- [7] FDA Drug Shortages database (2026). FDA
- [8] NDA 213051 S-030 approval letter (Ozempic tablets name) (2026). FDA
- [9] Wegovy tablets approval letter, NDA 218316 (2025). FDA
- [10] FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (2026). FDA
- [11] FDA's concerns with unapproved GLP-1 drugs used for weight loss (2026). FDA
- [12] NovoCare: Wegovy savings offer and self-pay pricing (2026). Company website
- [13] NovoCare: Ozempic savings offer and self-pay pricing (2026). Company website
- [14] Wilding JPH. Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021). PMID 33567185
- [15] Wilding JPH. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022). PMID 35441470
- [16] Lincoff AM. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023). PMID 37952131
- [17] Perkovic V. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (2024). PMID 38785209
- [18] Sanyal AJ. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (2025). PMID 40305708
- [19] Marso SP. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016). PMID 27633186
- [20] Wharton S. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (2025). PMID 40934115
- [21] Aronne LJ. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (2025). PMID 40353578
- [22] Rubino DM. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial (2022). PMID 35015037